Zanwar S, Gertz MA, Muchtar E (2023) Immunoglobulin light chain amyloidosis: diagnosis and risk assessment. J Natl Compr Canc Netw 21(1):83–90

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quock TP et al (2018) Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2(10):1046–1053

Article  PubMed  PubMed Central  Google Scholar 

Kumar N et al (2022) Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis 17(1):278

Article  PubMed  PubMed Central  Google Scholar 

Staron A et al (2021) Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J 11(8):139

Article  PubMed  PubMed Central  Google Scholar 

Palladini G et al (2023) The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J 13(1):19

Article  PubMed  PubMed Central  Google Scholar 

Muchtar E et al (2017) Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129(15):2111–2119

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar S et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oubari S et al (2024) Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica 109(1):220–230

CAS  PubMed  Google Scholar 

Kastritis E et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385(1):46–58

Article  CAS  PubMed  Google Scholar 

Wechalekar AD et al (2023) Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid 30(1):3–17

Article  CAS  PubMed  Google Scholar 

Khwaja J et al (2024) Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients. Haematologica. https://doi.org/10.3324/haematol.2023.284348

Article  PubMed  PubMed Central  Google Scholar 

Fotiou D, Theodorakakou F, Kastritis E (2021) Biomarkers in AL amyloidosis. Int J Mol Sci 22(20):10916

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jamet B et al (2021) Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging 48(4):1005–1015

Article  CAS  PubMed  Google Scholar 

Bohannan ZS, Coffman F, Mitrofanova A (2022) Random survival forest model identifies novel biomarkers of event-free survival in high-risk pediatric acute lymphoblastic leukemia. Comput Struct Biotechnol J 20:583–597

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rajkumar SV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548

Article  PubMed  Google Scholar 

Gertz MA et al. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 Apr 2004. pp. 319–328

Collins GS et al (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ (Clin Res Ed) 350:g7594

Google Scholar 

Garcia-Garcia HM et al (2019) Impact of periprocedural myocardial biomarker elevation on mortality following elective percutaneous coronary intervention. JACC Cardiovasc Interv 12(19):1954–1962

Article  PubMed  Google Scholar 

Jang JG et al (2020) Prognostic factors for severe coronavirus disease 2019 in Daegu, Korea. J Korean Med Sci 35(23):e209

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brenner DA et al (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94(8):1008–1010

Article  CAS  PubMed  Google Scholar 

Ghio S et al (2007) Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 9(8):808–813

Article  PubMed  Google Scholar 

Wang X et al (2022) Feasibility of (68)Ga-labeled fibroblast activation protein inhibitor PET/CT in light-chain cardiac amyloidosis. JACC Cardiovasc Imaging 15(11):1960–1970

Article  CAS  PubMed  Google Scholar 

Gertz MA, Kyle RA (1988) Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 85(1):73–80

Article  CAS  PubMed  Google Scholar 

Park MA et al (2003) Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine 82(5):291–298

Article  PubMed  Google Scholar 

Rosenzweig M, Kastritis E (2020) Liver and gastrointestinal involvement: update. Hematol Oncol Clin North Am 34(6S):e1–e13

Article  PubMed  Google Scholar 

Borovac JA et al (2020) Right ventricular free wall strain and congestive hepatopathy in patients with acute worsening of chronic heart failure: a CATSTAT-HF echo substudy. J Clin Med 9(5):1317

Article  PubMed  PubMed Central  Google Scholar 

Migrino RQ et al (2009) Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr 22(12):1396–1402

Article  PubMed  PubMed Central  Google Scholar 

Dittrich T et al (2019) Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104(7):1451–1459

Article  PubMed  PubMed Central  Google Scholar 

Palladini G et al (2014) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124(15):2325–2332

Article  CAS  PubMed  Google Scholar 

Jimenez-Zepeda V et al (2023) A comprehensive multidisciplinary diagnostic algorithm for the early and efficient detection of amyloidosis. Clin Lymphoma Myeloma Leuk 23(3):194–202

Article  CAS  PubMed  Google Scholar 

Yan W et al (2021) A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data from 1,064 Chinese patients. Ann Transl Med 9(16):1347–1347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor JMG (2011) Random survival forests. J Thorac Oncol 6(12):1974–1975

Article  PubMed  Google Scholar 

Dispenzieri A et al (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361(9371):1787–1789

Article  CAS  PubMed  Google Scholar 

Palladini G et al (2010) The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116(18):3426–3430

Article  CAS  PubMed  Google Scholar 

Kumar S et al (2023) Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid 30(3):268–278

Article  CAS  PubMed  Google Scholar 

Chakraborty R et al (2023) First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy. Br J Haematol 201(5):913–916

Article  CAS  PubMed  Google Scholar